FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284561540> ?p ?o ?g. }

• W2284561540 abstract "Acute Lymphoblastic Leukemia (ALL), the most common pediatric cancer, is an aggressive malignancy of lymphopoietic cells characterized by a clonal proliferation of blast cells originated from lymphoid precursors arrested at early stages of differentiation. Nowadays the introduction of risk-directed treatment and intensified cure protocols has improved the outcome of ALL pediatric patients. Although current therapies achieve five-year event-free survival rate of about 80% in children, the rest of patients experience treatment resistance and risk of early relapse. In order to develop new additional therapeutic supports and to assemble specific and personalized therapies, improving drug response and reducing drug toxicity, it is extremely important to identify novel therapeutic targets and new prognostic biomarkers on leukemic cells.To pursue this aim, Reverse Phase Protein Arrays (RPPA) approach represents a powerful tool to profile protein pathways in order to identify novel diagnostic and prognostic biomarkers. RPPA can measure the activation levels/phosphorylation of large numbers of signalling proteins from small clinical samples in a very reproducible, precise, sensitive and high-throughput manner. The identification of critical nodes or interactions within the protein network is a potential starting point for drug development and/or design of individual therapy regimens.In RPPA, protein lysates are immobilized on a nitrocellulose-coated glass slide. Each group of spots represents an individual test sample, such that an array is comprised of multiple, different samples. Each RPPA slide is probed with a single detection molecule (one slide = one antibody) and a single analyte is concurrently measured across multiple samples. This format allows multiple samples to be analyzed under the same experimental conditions for any given analyte. This approach facilitates comparisons between samples, since experimental variability is eliminated. During my PhD research I applied the Reverse Phase Protein Arrays (RPPA) technique to the study of patients affected by Acute Leukemia. The principal aim of this research was the discovery of new candidate biomarkers and therapeutic targets involved in the leukemic process through the study of the phosphoproteomic profiles of ALL pediatric patients (T-ALL and B-ALL) by means of the RPPA technique. In the study of pediatric T-ALL at diagnosis reported in the “Main Topic”, we identified PKC alpha as a new prognostic marker of relapse. This promising protein kinase has been identified through a retrospective RPPA screening of fifty-three different proteins/phophoproteins in 98 T-ALL specimens. PKC alpha resulted to be downregulated in the group of patients with a higher incidence of relapse. We showed that low PKC alpha activation is a consequence of a low PKC alpha gene Moreover, we induced PKC alpha inhibition in T-ALL cell lines using a PKC alpha commercial inhibitor and an increase in proliferation rate was detected. RPPA thus proved to be a useful approach to discover new molecules aberrantly expressed in leukemia pathways. The identification of players involved in malignant mechanisms allows focusing on novel prognostic factors: PKC alpha resulted to be a promising marker of risk of relapse in pediatric T-ALL. A study of PKC alpha expression in a larger T-ALL patients cohort should confirm this relevant data and to propose PKC alpha as a new prognostic marker for T-ALL patients stratification.In the pediatric B-cell precursor (BCP)-ALL study we used RPPA to map in 118 pediatric BCP-ALL patients for the expression/activation of 92 different proteins/phophoproteins part of key signalling “hubs”. Correlation of signalling activation with clinical response and known genetic information enabled us to identify new protein pathway biomarkers that, when validated in larger clinical sets, could be used for patients stratification and targeted therapy trials. In detail, we observed an increased activation/expression of several pathways involved in cell proliferation in patients with a clinical poor phenotype. First, MLL-rearranged leukemia revealed BCL-2 hyperphosphorylation caused by AMPK activation, indicating that AMPK could be responsible of apoptosis inhibition in MLL-rearranged patients and thus could be considered as a new potential therapeutic target. Second, in patients with poor clinical response to Prednisone we observed the up-modulation of LCK activity with respect to patients with good response. This tyrosine-kinase can be down-modulated with clinically used inhibitors that could be considered for further studies as a new additional therapy for Prednisone-resistant patients. Further we also found an association between high levels of CYCLIN E and relapse incidence. Moreover, CYCLIN E is more expressed in patients with early relapsed, who usually show an unfavourable prognosis. We decided to explore in deep the functional significance of AMPK activation in MLL-rearranged patients. We showed that the AMPK pathway contributes directly to the survival of MLL-rearranged BCP-ALL cells and AMPK can be considered a new druggable target in MLL-rearranged leukemias. RPPA reliability in detection of novel targets and markers has been demonstrated also in collaborative studies with national and international research groups, regarding also adult diseases such as Acute Myeloid Leukemia.In my PhD research I showed that the application of Reverse Phase Protein Arrays is a reliable, sensitive and high-throughput method to identify new aberrant molecular players involved in haematological malignancies. These findings will be useful in order to discover novel prognostic markers and therapeutic targets to propose for the development of more effective patient-tailored treatments" @default.
• W2284561540 created "2016-06-24" @default.
• W2284561540 creator A5061280642 @default.
• W2284561540 date "2012-01-29" @default.
• W2284561540 modified "2023-09-24" @default.
• W2284561540 title "Lack of Protein Kinase C alpha is associated with poor prognosis in pediatric T-ALL: a phosphoproteomic discovery" @default.
• W2284561540 cites W1266576439 @default.
• W2284561540 cites W1508623460 @default.
• W2284561540 cites W1510496295 @default.
• W2284561540 cites W1527712367 @default.
• W2284561540 cites W1537294787 @default.
• W2284561540 cites W1539110229 @default.
• W2284561540 cites W1555201740 @default.
• W2284561540 cites W1566064342 @default.
• W2284561540 cites W1576671418 @default.
• W2284561540 cites W1582379379 @default.
• W2284561540 cites W1596486131 @default.
• W2284561540 cites W1600640558 @default.
• W2284561540 cites W1639582946 @default.
• W2284561540 cites W1666872249 @default.
• W2284561540 cites W1844603538 @default.
• W2284561540 cites W1855059633 @default.
• W2284561540 cites W1918924349 @default.
• W2284561540 cites W1933105316 @default.
• W2284561540 cites W1963877296 @default.
• W2284561540 cites W1964648997 @default.
• W2284561540 cites W1965529803 @default.
• W2284561540 cites W1966971174 @default.
• W2284561540 cites W1967892265 @default.
• W2284561540 cites W1968633158 @default.
• W2284561540 cites W1968710298 @default.
• W2284561540 cites W1969094894 @default.
• W2284561540 cites W1969150166 @default.
• W2284561540 cites W1969474327 @default.
• W2284561540 cites W1969785844 @default.
• W2284561540 cites W1970262650 @default.
• W2284561540 cites W1971695868 @default.
• W2284561540 cites W1972344392 @default.
• W2284561540 cites W1972462568 @default.
• W2284561540 cites W1972816816 @default.
• W2284561540 cites W1973671181 @default.
• W2284561540 cites W1974604649 @default.
• W2284561540 cites W1975995627 @default.
• W2284561540 cites W1976767488 @default.
• W2284561540 cites W1976980370 @default.
• W2284561540 cites W1979608361 @default.
• W2284561540 cites W1982469575 @default.
• W2284561540 cites W1987080455 @default.
• W2284561540 cites W1987294127 @default.
• W2284561540 cites W1987534522 @default.
• W2284561540 cites W1987793183 @default.
• W2284561540 cites W1988383422 @default.
• W2284561540 cites W1988824838 @default.
• W2284561540 cites W1989039704 @default.
• W2284561540 cites W1992231131 @default.
• W2284561540 cites W1994041743 @default.
• W2284561540 cites W1999383552 @default.
• W2284561540 cites W1999532069 @default.
• W2284561540 cites W2000436912 @default.
• W2284561540 cites W2000589976 @default.
• W2284561540 cites W2001404876 @default.
• W2284561540 cites W2003181008 @default.
• W2284561540 cites W2004338566 @default.
• W2284561540 cites W2004652425 @default.
• W2284561540 cites W2004670453 @default.
• W2284561540 cites W2005624571 @default.
• W2284561540 cites W2007477730 @default.
• W2284561540 cites W2007610433 @default.
• W2284561540 cites W2010100216 @default.
• W2284561540 cites W2012592608 @default.
• W2284561540 cites W2016833582 @default.
• W2284561540 cites W2018527149 @default.
• W2284561540 cites W2020290519 @default.
• W2284561540 cites W2020638356 @default.
• W2284561540 cites W2020724252 @default.
• W2284561540 cites W2023941836 @default.
• W2284561540 cites W2024996887 @default.
• W2284561540 cites W2025183726 @default.
• W2284561540 cites W2025420184 @default.
• W2284561540 cites W2025580497 @default.
• W2284561540 cites W2025645148 @default.
• W2284561540 cites W2026195376 @default.
• W2284561540 cites W2026987638 @default.
• W2284561540 cites W2028562167 @default.
• W2284561540 cites W2030478913 @default.
• W2284561540 cites W2031034039 @default.
• W2284561540 cites W2033091093 @default.
• W2284561540 cites W2033733802 @default.
• W2284561540 cites W2034269086 @default.
• W2284561540 cites W2034592954 @default.
• W2284561540 cites W2036999612 @default.
• W2284561540 cites W2037896121 @default.
• W2284561540 cites W2039616075 @default.
• W2284561540 cites W2040711070 @default.
• W2284561540 cites W2042629507 @default.
• W2284561540 cites W2045813473 @default.
• W2284561540 cites W2046748396 @default.
• W2284561540 cites W2047893957 @default.
• W2284561540 cites W2049157915 @default.
• W2284561540 cites W2049740690 @default.

• next